Ocugen's Amsterdam Office Opens as a 250 Million Share Vote Stalls and Legal Scrutiny Mounts

Ocugen stock fell 2.8% to EUR 0.8810 as a shareholder probe and a stalled vote on 250 million new shares cloud its European expansion plans.

Ocugen finds itself navigating a widening gap between its international ambitions and the financial machinery needed to fund them. On Thursday, the stock slipped 2.8% to EUR 0.8810, a move that laid bare investor unease over a capital structure still in limbo.

That same day, U.S. law firm Halper Sadeh LLC disclosed it had launched a probe into officers and board members at the biotech. The shareholder-rights practice is examining whether company fiduciaries breached their duties to investors. The firm was careful to note that the announcement marks the start of an inquiry only — no wrongdoing has been established. What triggered Wednesday's 3.3% decline to EUR 0.8760 is not spelled out in any corporate filing.

A European Foothold Takes Shape

The legal cloud has gathered just as Ocugen lays the groundwork for a broader international footprint. On Tuesday, the company named Jolanda Crombach general manager of its newly formed European subsidiary in Amsterdam. Her mandate covers the buildout of European operations, support for the Phase 3 development of OCU410, planned European regulatory submissions, and eventual commercialization.

Management views Europe as the logical next market for its advanced programs. Yet a European subsidiary and the preparations for approval filings carry a price tag — and that is precisely where operational momentum collides with the owners of the company.

The Financing Standoff

Fresh capital remains frozen. A vote to authorize 250,000,000 additional shares of common stock had to be adjourned after the proposal failed to win approval. Shareholders will reconvene on October 26, 2026. The repeated postponement underscores the suspicion among existing investors toward massive dilution of their stakes. From the shareholder perspective, that resistance is understandable; for the operating business, it is a tangible obstacle. Late-stage clinical work of the kind surrounding OCU410 is capital-intensive. Without clarity on its financial runway soon, Ocugen's expansion plans risk running out of fuel, and the danger of delays grows with every deferred vote.

Clinical Timelines and Rising Costs

The company is pressing ahead with its own drug candidates in parallel. Roughly two weeks ago, it presented Phase 2 results from the ArMaDa study for candidate OCU410. Following that data release, the share price fell 1.9%. Solid efficacy data at this stage are seen as the prerequisite for justifying the heavy spending required in late-stage clinical development. Building out international subsidiaries, meanwhile, demands liquid resources — while market-ready products remain some way off.

The financial toll of this development effort shows clearly in the numbers. On August 25, Ocugen reported a net loss of $0.07 per share for the second quarter of 2026, compared with a loss of $0.05 in the year-earlier period. Operating expenses for the quarter climbed to $17.9 million. Key data readouts from the three Phase 3 programs are expected in 2027 and 2028.

Where the Stock Stands

With the current quote, the stock trades just above its 52-week low of EUR 0.8400. Year to date, the shares are down 30%. On balance, the uncertainties surrounding the capital increase currently weigh more heavily than the organizational groundwork being laid overseas. Until the blockade is resolved at the October 26, 2026 meeting, the stock is likely to stay vulnerable to setbacks. Much will hinge on whether management can still win shareholders over to its strategy — and whether the legal allegations can be put to rest promptly.